Sign in

CIK 0001907108 · <br>Emerging growth company

Lexeo Therapeutics, Inc.

Sign in to watch
Ticker
LXEO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
operating
EIN
854012572
Phone
(212) 547-9879
Business address
345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK, NY, 10010
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$43,228
in 3 filings

Net −$43,228. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Tamayo Louis Edward −$20K Chief Financial Officer sold 4% of stake
  2. Townsend Richard Nolan −$17K Chief Executive Officer sold <1% of stake
  3. Otero Jose Manuel −$6K Chief Operating Officer sold <1% of stake
Date Insider Transaction Shares Price Value Owned after
2025-05-16 Robertson Jenny Chief Legal Officer Sale −521 $2.77 $1K 63,098
2025-05-16 See Tai Sandi Chief Development Officer Sale −367 $2.77 $1K 59,242
2025-03-14 Otero Jose Manuel Chief Technical Officer Grant or award +5,720 $2.61 $15K 63,220
2025-03-14 Robertson Jenny Chief Legal Officer Grant or award +5,720 $2.61 $15K 63,619
2025-03-14 See Tai Sandi Chief Development Officer Grant or award +5,720 $2.61 $15K 59,609
2025-03-14 Townsend Richard Nolan Chief Executive Officer Grant or award +2,128 $2.61 $6K 222,247
2025-02-19 Townsend Richard Nolan Chief Executive Officer Sale −4,326 $4.41 $19K 220,119
2025-02-19 See Tai Sandi Chief Development Officer Sale −1,486 $4.41 $7K 53,889
2025-02-19 Adler Eric Chief Medical Officer Sale −2,359 $4.41 $10K 68,266
2025-02-19 Robertson Jenny Chief Legal Officer Sale −2,101 $4.41 $9K 57,899
2025-01-17 Rasbach Kyle Chief Financial Officer Grant or award +40,875 40,875
2025-01-17 Rasbach Kyle Chief Financial Officer Grant or award · Stock Option (right to buy) +245,250 245,250
2025-01-07 Townsend Richard Nolan Chief Executive Officer Grant or award +103,750 224,445
2025-01-07 Townsend Richard Nolan Chief Executive Officer Grant or award · Stock Option (right to buy) +207,500 207,500
2025-01-07 Otero Jose Manuel Chief Technical Officer Grant or award +26,250 57,500
2025-01-07 Otero Jose Manuel Chief Technical Officer Grant or award · Stock Option (right to buy) +52,500 52,500
2025-01-07 Robertson Jenny Chief Legal & Admin Officer Grant or award +36,250 60,000
2025-01-07 Robertson Jenny Chief Legal & Admin Officer Grant or award · Stock Option (right to buy) +72,500 72,500
2025-01-07 See Tai Sandi Chief Development Officer Grant or award +38,750 55,375
2025-01-07 See Tai Sandi Chief Development Officer Grant or award · Stock Option (right to buy) +77,500 77,500

Page 5 of 9 · 165 trades